A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ATOS
- Sponsors Sanofi
- 19 Feb 2019 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.
- 19 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2018 Planned End Date changed from 1 Dec 2019 to 1 Jan 2020.